01
A new report with an earlier data year
CDC's updated Antimicrobial Resistance Threats Report, dated October 27, 2026, brings together U.S. burden estimates for the organisms on its threat list. The headline figures are 9.7 million infections and 50,800 deaths annually. They describe the organisms covered by the report, not a count of newly detected infections in October.
The report aggregates 2023 estimates for 19 urgent, serious and concerning threats. Its scope also includes Clostridioides difficile, or C. diff, which CDC says is not typically drug-resistant: antibiotic use and the spread of germs are shared reasons for tracking it alongside resistance threats.
02
Keep the ranges and footnotes beside the totals
The published central estimates come with statistical uncertainty. CDC's burden table reports the following 95% intervals; these describe uncertainty in population-level estimates, rather than the chances that a particular person will become ill.
| Outcome | Central estimate | Published 95% interval |
|---|---|---|
| Infections | 9.7 million | 8.2–11.7 million |
| Deaths | 50,800 | 39,400–65,100 |
Even the data year needs a footnote. Although the table is headed “U.S. Burden Estimates, 2023,” its drug-resistant tuberculosis mortality entry uses 2021 data because treatment outcomes take longer to report. Other footnotes explain adjustments for overlapping pathogen groups. Adding every displayed row is not a substitute for CDC's combined estimate.
03
Why older headline totals are not a trend line
CDC says methods and data sources changed substantially for all pathogens except C. auris, and advises against directly comparing this report with earlier editions. Subtracting an older total from the new one cannot reliably separate a change in infections from a change in how the burden was measured.
C. diff provides a concrete example: previous reports included hospitalized cases, while this update includes hospitalized and non-hospitalized cases. CDC also moved it from the urgent to the serious category, while emphasizing that it still causes substantial illness and deaths. A broader count and a changed category answer different questions.
04
A practical way to check a report headline
Before quoting a number, save its data year, population and outcome together. Keep the uncertainty interval attached, then check whether the organism's definition or the settings included have changed. For a trend claim, look for a time series and its methods rather than treating successive report editions as interchangeable measurements.
These are Kadomony's reading steps, not a clinical checklist. The U.S. totals do not supply a Puerto Rico-specific or Japan-specific burden estimate, predict an individual's risk, or establish which treatment would work for someone.
05
What this report can support
The update helps describe the scale and range of threats that public-health systems need to monitor. It can support a more careful discussion of surveillance and prevention priorities. A national aggregate alone cannot establish that a particular community has an outbreak or that one hospital's care has improved or worsened.
Evidence scope: We read CDC's report overview and C. diff page, and extracted and visually checked both pages of its burden-estimates PDF. We did not reanalyse surveillance data, audit every pathogen's methods, or conduct an independent clinical review. This news report does not change Kadomony's evergreen treatment guidance.
Sources
- Antimicrobial Resistance Threats Report — all pathogens, assessment and changes since the last reportCenters for Disease Control and Prevention · 2026Source accessed:
- Antimicrobial Resistance Threats: U.S. Burden Estimates, 2023 — both pages and footnotesCenters for Disease Control and Prevention · 2026Source accessed:
- Clostridioides difficile — 2026 AR Threats Report pathogen profileCenters for Disease Control and Prevention · 2026Source accessed:
Revision history
- Initial report prepared with automated assistance on October 28, 2026. The CDC report overview, C. diff profile and both pages of the burden-estimates PDF were checked at 2026-10-28T01:16:24Z (UTC). The report's suggested citation is dated October 27; its principal burden estimates refer to 2023, with the TB mortality footnote referring to 2021. Source tables were extracted and visually inspected; surveillance data were not reanalysed and not every pathogen's methods document was audited. No independent clinical review is recorded. This is a news and evidence-interpretation report, not a change to individual treatment or Kadomony's evergreen guidance.